Eli Lilly and Company — China drug registrations and re-registration deadlines
13 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest re-registration deadline: 2026-09-15.
| Approval number | Product | Certificate expires | Re-registration deadline (Art. 82) |
|---|---|---|---|
| 国药准字SJ20220011 | Cyramza 雷莫西尤单抗注射液 | 2027-03-15 | 2026-09-15 |
| 国药准字SJ20220012 | Cyramza 雷莫西尤单抗注射液 | 2027-03-15 | 2026-09-15 |
| 国药准字SJ20190034 | TALTZ 依奇珠单抗注射液 | 2029-05-08 | 2028-11-08 |
| 国药准字HJ20150284 | Cymbalta 盐酸度洛西汀肠溶胶囊 | 2029-06-26 | 2028-12-26 |
| 国药准字HJ20150285 | Cymbalta 盐酸度洛西汀肠溶胶囊 | 2029-06-26 | 2028-12-26 |
| 国药准字HJ20150286 | Cymbalta 盐酸度洛西汀肠溶胶囊 | 2029-06-26 | 2028-12-26 |
| 国药准字HJ20150287 | Cymbalta 盐酸度洛西汀肠溶胶囊 | 2029-06-26 | 2028-12-26 |
| 国药准字SJ20240047 | Kisunla 多奈单抗注射液 | 2029-12-16 | 2029-06-16 |
| 国药准字SJ20260013 | Mirikizumab Injection 米吉珠单抗注射液 | 2031-02-09 | 2030-08-09 |
| 国药准字SJ20260014 | OMVOH 米吉珠单抗注射液（皮下注射） | 2031-02-09 | 2030-08-09 |
| 国药准字SJ20260015 | OMVOH 米吉珠单抗注射液（皮下注射） | 2031-02-09 | 2030-08-09 |
| 国药准字SJ20260016 | OMVOH 米吉珠单抗注射液（皮下注射） | 2031-02-09 | 2030-08-09 |
| 国药准字SJ20260017 | OMVOH 米吉珠单抗注射液（皮下注射） | 2031-02-09 | 2030-08-09 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.